Introduction
Chronic pain syndromes affect an estimated 20 percent of the global adult population and are a leading cause of disability and diminished quality of life. Conditions such as complex regional pain syndrome (CRPS), fibromyalgia, and neuropathic pain are often refractory to conventional analgesic strategies. Low-dose, subanesthetic ketamine has emerged as a mechanistically distinct intervention that addresses the neuroplastic changes underlying chronic pain states, particularly the phenomenon of central sensitization.
Pathophysiology of Central Sensitization
Chronic pain conditions share a common neurobiological feature: central sensitization. Sustained nociceptive input leads to pathological upregulation of NMDA receptor activity in dorsal horn neurons of the spinal cord and in supraspinal pain-processing centers. This amplified glutamatergic transmission reduces pain thresholds (allodynia), amplifies pain responses (hyperalgesia), and expands receptive fields. The NMDA receptor is therefore a logical and mechanistically rational pharmacological target in the management of chronic pain.
Mechanism of Ketamine in Pain Modulation
NMDA Receptor Blockade
At subanesthetic doses, ketamine provides use-dependent blockade of the NMDA receptor ion channel, preferentially antagonizing receptors that are pathologically active. This attenuates the wind-up phenomenon and reverses established central sensitization without producing full anesthesia. The result is a resetting of pain-processing circuitry toward normal baseline function.
Modulation of Descending Inhibitory Pathways
Ketamine also enhances descending inhibitory pain pathways through interactions with monoaminergic systems, opioid receptors (particularly the mu and kappa subtypes), and voltage-gated sodium channels. This multimodal mechanism distinguishes ketamine from conventional analgesics that target a single receptor system.
Anti-Inflammatory Properties
Emerging evidence suggests that ketamine possesses systemic anti-inflammatory effects, including suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6. Given the recognized role of neuroinflammation in chronic pain pathophysiology, this property may contribute meaningfully to analgesic efficacy.
Complex Regional Pain Syndrome
CRPS is a debilitating condition characterized by severe, disproportionate limb pain accompanied by autonomic dysfunction, edema, trophic changes, and motor impairment. It is among the most well-studied indications for ketamine infusion therapy in chronic pain.
Evidence Base
Multiple open-label studies and several randomized controlled trials have demonstrated significant pain reduction in CRPS patients receiving multi-day subanesthetic ketamine infusions. The landmark Sigtermans et al. (2009) trial showed that a continuous ketamine infusion over 4.2 days produced significant pain relief lasting up to 11 weeks compared to placebo. Protocols typically employ infusions at 0.1 to 0.5 mg/kg/hour over four to five consecutive days, often in a monitored inpatient or outpatient infusion center setting.
Functional Outcomes
Beyond numerical pain reduction, ketamine infusions for CRPS have been associated with improvements in range of motion, grip strength, and ability to participate in physical rehabilitation, which is critical for long-term recovery in this condition.
Fibromyalgia
Fibromyalgia is a centralized pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive dysfunction, and sleep disturbance. Central sensitization and impaired descending inhibition are central to its pathophysiology.
Clinical Data
Several controlled trials have evaluated single and serial ketamine infusions in fibromyalgia. Noppers et al. (2011) demonstrated that a single infusion of 0.5 mg/kg over 30 minutes significantly reduced pain for up to two weeks in a subset of patients. Graven-Nielsen et al. (2000) showed that ketamine abolished referred pain and temporal summation in fibromyalgia patients, providing direct evidence of NMDA receptor involvement. Serial infusion protocols appear to offer more sustained benefit, though optimal dosing and scheduling remain areas of active investigation.
Neuropathic Pain
Neuropathic pain arises from lesions or dysfunction within the somatosensory nervous system and includes conditions such as diabetic peripheral neuropathy, post-herpetic neuralgia, and spinal cord injury pain. These conditions are notoriously difficult to treat, with first-line agents (gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants) providing meaningful relief in only 30 to 50 percent of patients.
Ketamine Infusion Data
A Cochrane systematic review and subsequent meta-analyses have found moderate-quality evidence supporting short-term analgesic efficacy of subanesthetic ketamine infusions in neuropathic pain states. Effect sizes are generally moderate, with number needed to treat estimates ranging from three to five for 30 percent pain reduction. Duration of benefit following single infusions is typically one to two weeks, with serial protocols extending response.
Infusion Protocols and Practical Considerations
Dosing
For chronic pain, ketamine infusion rates are commonly initiated at 0.1 to 0.2 mg/kg/hour and titrated based on tolerability and response, with most protocols not exceeding 0.5 mg/kg/hour. Multi-day continuous infusions at lower rates and intermittent bolus protocols at higher rates each have supporting literature and should be tailored to the specific condition and clinical setting.
Monitoring
Cardiorespiratory monitoring including continuous pulse oximetry, blood pressure measurement at defined intervals, and electrocardiographic monitoring is standard. Dissociative and psychotomimetic side effects should be assessed using validated instruments. Many centers co-administer low-dose midazolam or ondansetron to manage dissociation and nausea respectively.
Multimodal Integration
Ketamine infusion therapy for chronic pain achieves its greatest utility when integrated into a comprehensive, multimodal pain management plan that includes physical therapy, psychological support, interventional procedures, and pharmacotherapy. Ketamine should not be viewed as a standalone cure but as a tool to reduce central sensitization and create a therapeutic window for rehabilitation.
Conclusion
Low-dose ketamine addresses chronic pain at a mechanistic level distinct from conventional analgesics, targeting the NMDA-receptor-dependent central sensitization that sustains conditions such as CRPS, fibromyalgia, and neuropathic pain. Its evidence base continues to mature, and ongoing clinical trials are refining protocols for optimal efficacy and durability.
References
- PubMed: Ketamine Infusions for Chronic Pain: Systematic Review and Meta-Analysis of RCTs — Meta-analysis of randomized controlled trials evaluating IV ketamine for refractory chronic pain
- StatPearls: Ketamine in Acute and Chronic Pain Management — NCBI Bookshelf reference covering ketamine pharmacology, indications, and consensus guidelines for pain management
- PubMed: Ketamine for Chronic Pain: Risks and Benefits — Review of ketamine risk-benefit profile in chronic pain conditions
- CDC: Clinical Practice Guideline for Prescribing Opioids for Pain — CDC guidelines for pain management including context for non-opioid alternatives
Share